Drug Name Cytarabine
Found 8 free book(s)
DRUG NAME: Cytarabine - BC Cancer
www.bccancer.bc.caCytarabine DRUG NAME: Cytarabine SYNONYM(S): 1-B-arabinofuranosylcytosine, 1 arabinosylcytosine, 1 ara-C, 1 cytosine arabinoside 1 COMMON TRADE NAME(S): CYTOSAR® CLASSIFICATION: antimetabolite 1 Special pediatric considerations are noted when applicable, otherwise adult provisions apply.
DRUG NAME: Hydroxyurea - BC Cancer
www.bccancer.bc.caDRUG NAME: Hydroxyurea SYNONYM(S): hydroxycarbamide 1 ... The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event ... increased cytarabine therapeutic and toxic effects ...
DRUG NAME Gemcitabine - BC Cancer
www.bccancer.bc.caDRUG NAME: Gemcitabine ... Gemcitabine, a pyrimidine analog, is structurally similar to cytarabine, but has a wider spectrum of antitumour activity due to its different cellular pharmacology and mechanism of action.1 Gemcitabine is metabolized intracellularly to two active metabolites, gemcitabine diphosphate (dFdCDP) and gemcitabine ...
NSSG Chemotherapy Protocol
nssg.oxford-haematology.org.ukDRUG REGIMEN Days 1 to 7 G-CSF subcutaneous. As per local policy (up to 28 days). (e.g. Filgrastim 0.5microgram/kg/day) Days 2 to 6 FLUDARABINE 30 mg/m2 daily in 100 mL sodium chloride 0.9% intravenous infusion over 30 minutes (5 doses). Fludarabine infusion must precede the administration of cytarabine by 4 hours.
DRUG NAME: Fludarabine
www.bccancer.bc.caDRUG NAME: Fludarabine SYNONYM(S): 9-B-D-arabinofuranosyl-2-fluoroadenine 5’-monophosphate, 1 FAMP, 2,3 2-fluoro-ara-A Monophosphate, 3 2-fluoro-ara-AMP, 1,3 fludarabine phosphate, 1 NSC-312887 1. COMMON TRADE NAME(S): FLUDARA CLASSIFICATION: antimetabolite. 1. Special pediatric considerations are noted when applicable, otherwise adult ...
Blue Cross and BCN utilization management medical drug …
www.bcbsm.comLists any preferred products that a member must try and fail before receiving a drug. When a cell is blank, there is no preferred product information for that drug. Note: Medical benefit drug policies are a source for Blue Cross and BCN medical policy information. Medical policies are not to be used to determine benefits or reimbursement.
2021 Service Benefit Plan Specialty Drug List
www.myprime.comThe specialty drug list is updated monthly and is subject to change without notice. If you are a member or health-care provider and have specialty drug-specific questions, please call 1- 888-346-3731 weekdays from 7 a.m. to 9 p.m. or weekends from 8 a.m. to 6:30 p.m. Eastern time.
CYTARABINE (ARA-C) HIGH DOSE
nssg.oxford-haematology.org.ukCYTARABINE Prof HD Authorised by Myeloid Lead Adam Mead Oct 2019 Version 4.2 1 of 3 CYTARABINE (ARA-C) HIGH DOSE INDICATION Consolidation chemotherapy for AML in remission. Consider dose reduction to 1.5g/m2 for patient ≥60 years old and for patient under 60 years old with co-morbidities at the discretion of clinician and as discussed at the MDT.